April 26, 2013
By:
Global Telecom Testing
Companies are losing clients and compromising their global clinical trials because the worldwide telephone numbers assigned to these trials are flawed. Participants and doctors calling to report critical trial data often cannot due to non-operational telephone numbers. The time and money spent to fix these faulty telephone numbers is costly, frustrating, and compromises the clinical trial and its success.
|
May 1, 2013
By:
Dirk Reitsma, MD, Scott Berry, Ph.D., PPD, Inc.
Adaptive trial designs offer the means to make oncology trials more informative and efficient by leveraging accruing data to refine study parameters and decision-making as the trial progresses. This whitepaper discusses the use of adaptive trial design in oncology to improve Phase I dose determination, make Phase II trials more informative and gain efficiency in Phase III development.
|
January 15, 2013
By:
Medidata Solutions
This complimentary report provides benchmark costs for the 15 most common study procedures. Site grants can constitute approximately 40% of a study’s overall costs. Built from the proprietary PICAS® database of benchmark trial costs, this informative report will help sponsors build study site budgets that are fair market value defensible.
|
March 1, 2013
By:
Simon Sparkes, ArisGlobal
Most sites will fail to meet enrollment rates and studies will be extended beyond expected timelines. This white paper discusses how CTMS combined with planning tools can mitigate these risks.
|
November 6, 2012
By:
Molly Blake-Michaels, Consulting Solutions Expert, Oracle Health Sciences, Rachel Yagur, Principal Consultant, Oracle Health Sciences, Oracle
Under the current global operating environment, biopharmaceutical and medical device companies face far more limited financial resources, while time-to-market pressures are intensifying and worldwide clinical research activity is rising steadily. In response, companies are placing more demand on their planning and forecasting processes and capabilities and setting lower tolerances for variance between planned and actual performance.
|
October 25, 2012
By:
Gerd Arold, MD, Senior Director, Scientific Affairs, PRA International
Recent trends have seen first-into-man trials moving to patient populations earlier in drug development process. One issue still hampers this model: how to recruit patients? Traditional recruitment methods have consistently failed to get a sufficient number of patients into studies conducted in phase I units. One recruitment model which has proven successful is to reverse the paradigm. Rather than asking the patient to come to the unit, take the unit to the patient.
|
September 17, 2012
By:
Cara Danchak, Bonnie A. Brescia, CenterWatch
Two patient recruitment experts offer insight about the challenges and potential benefits of social media and online patient recruitment. Topics include: public perception, consumer trust and ethical considerations.
|
September 1, 2012
By:
Novella Clinical
Explore effective strategies in identifying, enrolling and retaining patients for oncology studies through a thoughtful and conservative resource approach. Understand protocol design specific to patient availability, identify key criteria in site selection and learn effective ways to maximize patient retention.
|
July 19, 2011
By:
Lionel Hovsepian, MD
This paper provides a review of metabolic syndrome and addresses the challenges of developing an effective clinical trial program for this indication, including subject recruitment and study design.
|
|
Facebook
Quizzes
